Lower sphingomyelins and higher ceramides in Alzheimer's patients are independent of statin use. HanXianlin RozenSteve H. BoyleStephen HellegersCaroline ChengHua BurkeJames R. A. Welsh-BohmerKathleen Murali DoraiswamyP. Kaddurah-DaoukRima 2013 <p>Panel A shows the differences in sphingomyelin and ceramide mass levels between AD patients and controls who were taking statins. For this comparison, P = 7×10<sup>−4</sup> for sphingomyelins and P = 0.00054 for ceramides (Wilcoxon signed rank test). Panel B shows the differences of sphingomyelin and ceramide mass levels between AD patients and controls who were not taking statins. For this comparison, P = 3.2×10<sup>−8</sup> for sphingomyelins and P = 0.0056 for ceramides (Wilcoxon signed rank test).</p>